First Time Loading...

Puma Biotechnology Inc
NASDAQ:PBYI

Watchlist Manager
Puma Biotechnology Inc Logo
Puma Biotechnology Inc
NASDAQ:PBYI
Watchlist
Price: 4.83 USD -5.85% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

Puma Biotechnology, Inc. is a biopharmaceutical company. [ Read More ]

The intrinsic value of one PBYI stock under the Base Case scenario is 4.92 USD. Compared to the current market price of 4.83 USD, Puma Biotechnology Inc is Undervalued by 2%.

Key Points:
PBYI Intrinsic Value
Base Case
4.92 USD
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Puma Biotechnology Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling PBYI stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Puma Biotechnology Inc

Provide an overview of the primary business activities
of Puma Biotechnology Inc.

What unique competitive advantages
does Puma Biotechnology Inc hold over its rivals?

What risks and challenges
does Puma Biotechnology Inc face in the near future?

Has there been any significant insider trading activity
in Puma Biotechnology Inc recently?

Summarize the latest earnings call
of Puma Biotechnology Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Puma Biotechnology Inc.

Provide P/S
for Puma Biotechnology Inc.

Provide P/E
for Puma Biotechnology Inc.

Provide P/OCF
for Puma Biotechnology Inc.

Provide P/FCFE
for Puma Biotechnology Inc.

Provide P/B
for Puma Biotechnology Inc.

Provide EV/S
for Puma Biotechnology Inc.

Provide EV/GP
for Puma Biotechnology Inc.

Provide EV/EBITDA
for Puma Biotechnology Inc.

Provide EV/EBIT
for Puma Biotechnology Inc.

Provide EV/OCF
for Puma Biotechnology Inc.

Provide EV/FCFF
for Puma Biotechnology Inc.

Provide EV/IC
for Puma Biotechnology Inc.

Show me price targets
for Puma Biotechnology Inc made by professional analysts.

What are the Revenue projections
for Puma Biotechnology Inc?

How accurate were the past Revenue estimates
for Puma Biotechnology Inc?

What are the Net Income projections
for Puma Biotechnology Inc?

How accurate were the past Net Income estimates
for Puma Biotechnology Inc?

What are the EPS projections
for Puma Biotechnology Inc?

How accurate were the past EPS estimates
for Puma Biotechnology Inc?

What are the EBIT projections
for Puma Biotechnology Inc?

How accurate were the past EBIT estimates
for Puma Biotechnology Inc?

Compare the revenue forecasts
for Puma Biotechnology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Puma Biotechnology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Puma Biotechnology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Puma Biotechnology Inc compared to its peers.

Compare the P/E ratios
of Puma Biotechnology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Puma Biotechnology Inc with its peers.

Analyze the financial leverage
of Puma Biotechnology Inc compared to its main competitors.

Show all profitability ratios
for Puma Biotechnology Inc.

Provide ROE
for Puma Biotechnology Inc.

Provide ROA
for Puma Biotechnology Inc.

Provide ROIC
for Puma Biotechnology Inc.

Provide ROCE
for Puma Biotechnology Inc.

Provide Gross Margin
for Puma Biotechnology Inc.

Provide Operating Margin
for Puma Biotechnology Inc.

Provide Net Margin
for Puma Biotechnology Inc.

Provide FCF Margin
for Puma Biotechnology Inc.

Show all solvency ratios
for Puma Biotechnology Inc.

Provide D/E Ratio
for Puma Biotechnology Inc.

Provide D/A Ratio
for Puma Biotechnology Inc.

Provide Interest Coverage Ratio
for Puma Biotechnology Inc.

Provide Altman Z-Score Ratio
for Puma Biotechnology Inc.

Provide Quick Ratio
for Puma Biotechnology Inc.

Provide Current Ratio
for Puma Biotechnology Inc.

Provide Cash Ratio
for Puma Biotechnology Inc.

What is the historical Revenue growth
over the last 5 years for Puma Biotechnology Inc?

What is the historical Net Income growth
over the last 5 years for Puma Biotechnology Inc?

What is the current Free Cash Flow
of Puma Biotechnology Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Puma Biotechnology Inc.

Financials

Balance Sheet Decomposition
Puma Biotechnology Inc

Current Assets 156.2m
Cash & Short-Term Investments 95.9m
Receivables 47.8m
Other Current Assets 12.4m
Non-Current Assets 74.3m
PP&E 8.6m
Intangibles 60.9m
Other Non-Current Assets 4.8m
Current Liabilities 99.4m
Accounts Payable 6.9m
Accrued Liabilities 57.5m
Other Current Liabilities 35m
Non-Current Liabilities 77.7m
Long-Term Debt 65.7m
Other Non-Current Liabilities 12m
Efficiency

Earnings Waterfall
Puma Biotechnology Inc

Revenue
235.6m USD
Cost of Revenue
-62.7m USD
Gross Profit
173m USD
Operating Expenses
-139.7m USD
Operating Income
33.3m USD
Other Expenses
-11.7m USD
Net Income
21.6m USD

Free Cash Flow Analysis
Puma Biotechnology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

PBYI Profitability Score
Profitability Due Diligence

Puma Biotechnology Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

51/100
Profitability
Score

Puma Biotechnology Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

PBYI Solvency Score
Solvency Due Diligence

Puma Biotechnology Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Long-Term Solvency
Average D/E
34/100
Solvency
Score

Puma Biotechnology Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PBYI Price Targets Summary
Puma Biotechnology Inc

Wall Street analysts forecast PBYI stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PBYI is 4.42 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.

Lowest
Price Target
2.02 USD
58% Downside
Average
Price Target
4.42 USD
8% Downside
Highest
Price Target
7.35 USD
52% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

PBYI Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

PBYI Price
Puma Biotechnology Inc

1M 1M
-14%
6M 6M
+117%
1Y 1Y
+78%
3Y 3Y
-53%
5Y 5Y
-86%
10Y 10Y
-93%
Annual Price Range
4.83
52w Low
2.23
52w High
7.4
Price Metrics
Average Annual Return -23.01%
Standard Deviation of Annual Returns 56.71%
Max Drawdown -95%
Shares Statistics
Market Capitalization 230.1m USD
Shares Outstanding 48 207 200
Percentage of Shares Shorted 8.01%

PBYI Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Puma Biotechnology Inc Logo
Puma Biotechnology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

230.1m USD

Dividend Yield

0%

Description

Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 196 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Contact

CALIFORNIA
Los Angeles
10880 Wilshire Blvd Ste 2150
+14242486500.0
https://www.pumabiotechnology.com/

IPO

2012-03-21

Employees

196

Officers

Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
CFO & Principal Accounting Officer
Mr. Maximo F. Nougues
Chief Scientific Officer
Dr. Alvin F. Wong Pharm.d.
Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law
Mr. Douglas Hunt B.Sc., FRAPS
Chief Commercial Officer
Mr. Jeffrey Jerome Ludwig
Senior Director of Investor Relations
Mr. Mariann Ohanesian

See Also

Discover More
What is the Intrinsic Value of one PBYI stock?

The intrinsic value of one PBYI stock under the Base Case scenario is 4.92 USD.

Is PBYI stock undervalued or overvalued?

Compared to the current market price of 4.83 USD, Puma Biotechnology Inc is Undervalued by 2%.